PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

被引：0

作者：

Mingtong Xu

Xiaoxue Zhu

Junyan Wu

Yuling Zhang

Dong Zhao

Xuhong Wang

Yanhua Ding

Yu Cao

Chengqian Li

Wei Hu

Jianlong Sheng

Zhu Luo

Zeqi Zheng

Jinfang Hu

Jianying Liu

Xiaoyang Zhou

Aizong Shen

Xiaomei Ding

Yongdong Zhang

Yonggang Zhao

Yijing Li

Sheng Zhong

Shimin An

Jianjun Zou

Li Yan

机构：

[1] Sun Yat-Sen University,Department of Endocrinology, Sun Yat

[2] The First Hospital of Jilin University,Sen Memorial Hospital

[3] Sun Yat-Sen University,Phase I Clinical Trials Unit

[4] Sun Yat-Sen University,Department of Pharmacy, Sun Yat

[5] Capital Medical University,Sen Memorial Hospital

[6] Beijing Luhe Hospital,Department of Cardiology, Sun Yat

[7] The Affiliated Hospital of Qingdao University,Sen Memorial Hospital

[8] The Affiliated Hospital of Qingdao University,Endocrinology Center

[9] The Second Hospital of Anhui Medical University,Phase I Clinical Research Center

[10] The Second Affiliated Hospital of Anhui Medical University,Department of Endocrinology

[11] Sichuan University,Department of Pharmacology

[12] The First Affiliated Hospital of Nanchang University,Department of Cardiology

[13] The First Affiliated Hospital of Nanchang University,Department of Clinical Laboratory Medicine, West China Hospital

[14] The First Affiliated Hospital of Nanchang University,Department of Cardiology

[15] Renmin Hospital of Wuhan University,Department of Pharmacy

[16] Anhui Provincial Hospital Affiliated to Anhui Medical University,Department of Endocrinology and Metabolism

[17] Anhui Provincial Hospital Affiliated to Anhui Medical University,Department of Cardiology

[18] Chenzhou First People’s Hospital,Department of Pharmacy

[19] Chenzhou First People’s Hospital,Department of Cardiology

[20] Jiangsu Hengrui Pharmaceuticals Co.,Department of Pharmacy

[21] Ltd.,Department of Emergency Medicine

来源：

BMC Medicine | / 20卷

关键词：

PCSK9; Hypercholesterolemia; Recaticimab; Infrequent administration;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study
Xu, Mingtong
Zhu, Xiaoxue
Wu, Junyan
Zhang, Yuling
Zhao, Dong
Wang, Xuhong
Ding, Yanhua
Cao, Yu
Li, Chengqian
Hu, Wei
Sheng, Jianlong
Luo, Zhu
Zheng, Zeqi
Hu, Jinfang
Liu, Jianying
Zhou, Xiaoyang
Shen, Aizong
Ding, Xiaomei
Zhang, Yongdong
Zhao, Yonggang
Li, Yijing
Zhong, Sheng
An, Shimin
Zou, Jianjun
Yan, Li
BMC MEDICINE, 2022, 20 (01)
[2] PCSK9 MONOCLONAL ANTIBODY RECATICIMAB IN ADULT HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (REMAIN-3): A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY
Chen Jiyan
Li, Liwen
Gao, Xiaojian
Zhou, Yujie
Xia, Shuang
Sheng Jianlong
Peng, Daoquan
Ling, Zhiyu
Wang, Luya
Zhong, Tingyan
Dai, Cuilian
Huang, Kai
Lian, Qiufang
Yu, Zaixin
Wang, Ying
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1707 - 1707
[3] Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Kohli, Payal
Desai, Nihar R.
Giugliano, Robert P.
Kim, Jae B.
Somaratne, Ransi
Huang, Fannie
Knusel, Beat
McDonald, Shannon
Abrahamsen, Timothy
Wasserman, Scott M.
Scott, Robert
Sabatine, Marc S.
CLINICAL CARDIOLOGY, 2012, 35 (07) : 385 - 391
[4] Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia
Lynch, David R.
Hauser, Lauren
McCormick, Ashley
Wells, McKenzie
Dong, Yi Na
McCormack, Shana
Schadt, Kim
Perlman, Susan
Subramony, Sub H.
Mathews, Katherine D.
Brocht, Alicia
Ball, Julie
Perdok, Renee
Grahn, Amy
Vescio, Tom
Sherman, Jeffrey W.
Farmer, Jennifer M.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2019, 6 (03): : 546 - 553
[5] Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Raal, Frederick
Stein, Evan
Scott, Rob
Somaratne, Ransi
Bridges, Ian
Wasserman, Scott M.
CIRCULATION, 2012, 126 (23) : 2781 - 2782
[6] Efficacy and Safety of Ebronucimab, a Monoclonal Antibody Against Pcsk9, in Patients With Hyperlipidemia: Result From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Zhen, Wang
Pei, Zhaohui
Chen, Jiyan
Zhang, Guogang
Li, Dongye
Xia, Yu
Li, Baiyong
Wang, Max
Ni, Xiang
Wang, Guoqin
Ge, Junbo
CIRCULATION, 2022, 146
[7] The Double-Blind Durable Effect of PCSK9 Antibody Compared with Placebo Study (DESCARTES): A 52 Week Phase 3 Double-Blind, Randomized, Placebo-Controlled Trial of Evolocumab (AMG 145) in Hyperlipidemic Patients
Blom, D.
Hala, T.
Bolognese, M.
Lillestol, M. J.
Toth, P. D.
Burgess, L.
Ceska, R.
Roth, E.
Koren, M. J.
Monsalvo, M. L.
Tsirtsonis, K.
Kim, J. B.
Wasserman, S. M.
Scott, R.
Ballantyne, C. M.
Somaratne, R.
Stein, E. A.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2014, 21 : S7 - S7
[8] RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-ESCALATION PHASE 1 STUDY OF AEROSOLIZED PIRFENIDONE
Khoo, J.
Montgomery, B.
Otto, K.
Surber, M.
Glaspole, I
RESPIROLOGY, 2019, 24 : 177 - 177
[9] A randomized, double-blind, placebo-controlled, Phase 2 study: the efficacy of fasudil in patients with stable angina
Vicari, RM
Smith, WB
Chaitman, B
Chrysant, SG
Tonkon, MJ
Bitter, N
Weiss, RJ
Thadani, U
EUROPEAN HEART JOURNAL, 2004, 25 : 138 - 138
[10] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
Goodman, A. D.
Rossman, H.
Bar-Or, A.
Miller, A.
Miller, D. H.
Schmierer, K.
Lublin, F.
Khan, O.
Bormann, N. M.
Yang, M.
Panzara, M. A.
Sandrock, A. W.
NEUROLOGY, 2009, 72 (09) : 806 - 812

← 1 2 3 4 5 →